Browse the evidence

GCGR/GLP-1 dual agonists (e.g., mazdutide, survodutide) and GCGR/GLP-1/GIP triple agonists (e.g., retatrutide) elicit substantial body weight reduction (up to 24.2%) and improve liver health in patients with obesity and MASLD/MASH.

For individuals with obesity and liver fat, newer once-weekly injections targeting the glucagon and GLP-1 receptors (and sometimes GIP) are showing remarkable results, with some patients losing over 20% of their body weight and seeing improvements in liver health. These are prescription medications requiring medical supervision, but they represent a significant advancement over older treatments.

Back squat training produces greater thigh hypertrophy (quadriceps and adductors) compared to hip thrust training.

If you want bigger quads and inner thighs, you need to do squats. Hip thrusts are great for glutes, but they don't build the rest of your legs as well as squats do.

Semaglutide (2.4 mg once-weekly) significantly reduces the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its components (steatosis, inflammation, ballooning) in patients with overweight/obesity and type 2 diabetes compared to placebo.

If you have overweight/obesity and type 2 diabetes, semaglutide (2.4 mg weekly) is a clinically proven treatment to significantly reduce liver fat, inflammation, and scarring (MASH/MASLD) compared to placebo. This is particularly relevant if lifestyle changes alone have not resolved liver issues. The treatment involves a weekly injection and is supported by strong statistical evidence from large clinical trials.

Retatrutide (12mg weekly) achieves 24.2% weight loss, rivaling bariatric surgery outcomes.

Retatrutide 12mg weekly can lead to ~24% weight loss. This is the highest efficacy reported in this review, rivaling surgery.

CagriSema (Cagrilintide + Semaglutide) achieves 22.7% weight loss, outperforming semaglutide alone.

CagriSema, a combination of Cagrilintide and Semaglutide, can lead to ~23% weight loss. It is more effective than Semaglutide alone.

GLP-1 receptor agonists (e.g., tirzepatide, danuglipron) produce significant weight loss and glycemic improvement in type 2 diabetes and obesity, with weight loss and glycemic effects being partially independent mechanisms.

GLP-1 based medications like tirzepatide are highly effective for weight loss (15-21%) and blood sugar control. Be aware that gastrointestinal side effects are common and may lead some to stop treatment, but the dual benefit is significant. Discuss dosing strategies with your provider to manage side effects.

A supervised 16-week strength training program performed at 70% 1RM with high volume induces significant strength gains, lean body mass increases, and favorable cardiac remodeling (LV/LA enlargement without functional impairment) in previously untrained women, with magnitude of adaptation similar to or exceeding that of men.

Perform supervised strength training 3 times a week at 70% of your one-rep max. Focus on compound movements (squats, presses, rows). Expect significant strength and lean mass gains within 16 weeks, comparable to men, along with improved heart health markers like ventricular enlargement without functional loss.

Among adherent participants (completing ≥80% of coaching calls), the same remote weight loss intervention resulted in significant weight loss compared to non-adherent participants.

If you can commit to the full program, including regular check-ins, significant weight loss is possible. The key is adherence, which may require more support or tailored engagement strategies for cancer survivors.

In patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), achieving a baseline Body Mass Index (BMI) of 30 kg/m² or higher is a significant independent predictor of achieving clinically relevant weight loss (≥7% of initial body weight) through lifestyle interventions.

If you have MASLD and a BMI of 30 or higher, you are statistically more likely to achieve significant weight loss through lifestyle changes than someone with a lower BMI. This is likely due to higher energy expenditure at rest. Use this advantage by committing to the lifestyle changes early, as your body is primed to respond to caloric deficits more robustly than those with lower baseline weights.

Utilization of Glucagon-like peptide-1 (GLP-1) receptor agonists for Type 2 Diabetes is a significant independent predictor of achieving relevant weight loss (≥7%) in MASLD patients, with odds ratios increasing for greater weight loss thresholds.

If you have MASLD and Type 2 Diabetes, using a GLP-1 agonist significantly increases your chances of losing enough weight to improve your liver health. The data shows that users are over 4 times more likely to lose 10% or more of their body weight compared to non-users. Discuss this option with your doctor as part of a comprehensive MASLD management plan.

Engagement with a nutritionist is a significant independent predictor of achieving relevant weight loss (≥7% and ≥10%) in MASLD patients, even when controlling for baseline BMI and other comorbidities.

If you have MASLD, seeking help from a qualified nutritionist significantly increases your chances of losing enough weight to improve your liver health. The study shows that patients who worked with a nutritionist were nearly 4 times more likely to lose 10% or more of their body weight. Make this a priority in your care plan.

GLP-1 receptor agonists (GLP-1RAs) as adjunctive therapy to insulin significantly reduce body weight, HbA1c, and total daily insulin requirements in patients with type 1 diabetes and overweight or obesity.

If you have Type 1 Diabetes and are overweight, adding a GLP-1RA (like semaglutide or liraglutide) to your insulin regimen can help you lose weight (average 4-6 kg), lower your HbA1c slightly, and significantly reduce your daily insulin needs (by ~9 units). This is generally safe, though you may experience temporary nausea and a slightly higher risk of low blood sugar, which can be managed by adjusting your insulin dose.

Semaglutide demonstrates superior efficacy in reducing body weight, HbA1c, and insulin requirements compared to other GLP-1RAs (liraglutide, exenatide) in patients with Type 1 Diabetes.

Among GLP-1RAs, semaglutide (1.0 mg weekly) appears to be the most effective option for Type 1 Diabetes patients, offering greater weight loss (~6 kg) and insulin reduction (~15 units/day) compared to liraglutide or exenatide. Discuss with your provider if you are a candidate for this specific agent.

Orforglipron, an oral non-peptide GLP-1 receptor agonist, produces dose-dependent reductions in body weight (up to 9.8% at 45 mg) and waist circumference, with maximal efficacy observed at higher doses (24-45 mg).

Orforglipron is an oral medication that helps obese adults lose weight and improve metabolic markers like blood sugar and cholesterol. It works by mimicking a natural hormone (GLP-1) to reduce appetite and slow digestion. The higher the dose (up to 45 mg daily), the more weight is lost, with studies showing up to 9.8% body weight reduction. However, higher doses also increase the risk of stomach issues like nausea and diarrhea, which may lead some patients to stop taking it. It is taken once daily without strict fasting requirements, making it more convenient than some injectable alternatives.

Lifestyle interventions (diet and exercise) are effective in preventing or delaying Type 2 Diabetes in high-risk groups, including those with a history of GDM, but adherence remains a significant barrier.

For women with a history of GDM, aiming for 150 minutes of physical activity per week combined with dietary changes is the most effective way to prevent Type 2 Diabetes. Structured programs offering health coaching and group support can improve adherence and outcomes. Regular monitoring of HbA1c and fasting plasma glucose is recommended.

Treatment with semaglutide 2.4 mg for overweight or obesity leads to a statistically significant reduction in the need for concomitant antihypertensive and lipid-lowering medications compared to placebo, primarily through weight-loss-mediated improvements in blood pressure and lipid profiles.

If you are taking medication for high blood pressure or high cholesterol, significant weight loss achieved through semaglutide 2.4 mg may allow your doctor to safely lower your dose or stop the medication entirely. This is not automatic; it requires active monitoring by your healthcare provider to ensure your blood pressure and lipids remain in a healthy range without the drugs. Do not stop these medications on your own.

Intentional weight loss achieved through lifestyle interventions, antiobesity medications, or bariatric surgery reduces the incidence of obesity-associated cancers, particularly hormone-dependent malignancies in postmenopausal women.

If you have overweight or obesity, achieving and maintaining a weight loss of at least 5% of your body weight can significantly reduce your risk of developing certain cancers, especially in postmenopausal women. This can be achieved through lifestyle changes (diet and exercise), medications, or surgery. The key is sustained loss, not just short-term dieting.

Intensive, frequent dietitian-supported nutritional education significantly reduces total energy and carbohydrate intake in patients with type 2 diabetes compared to standard annual education.

For patients with Type 2 Diabetes, especially those with kidney issues, seeing a dietitian frequently (at every visit) is more effective for reducing calorie and carb intake than seeing them once a year. This frequent support helps patients make better food choices, such as eating more fish and fewer sweets, leading to significant reductions in total energy intake over two years.

Phenotype-guided pharmacotherapy using naltrexone/bupropion extended-release (NB-ER) is the preferred treatment for obesity patients with emotional hunger, as it addresses both weight and depression symptoms.

If you struggle with emotional eating and depression, ask your doctor about NB-ER (naltrexone/bupropion). It is specifically shown to help with both weight loss and mood in this subgroup, unlike many standard antidepressants which may cause weight gain.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) are effective for weight loss in patients with obesity and may improve depression scores, with a low rate of adverse psychiatric events.

GLP-1 agonists (like Semaglutide or Tirzepatide) are highly effective for weight loss (15-21%) and may also improve depression. They have a low risk of psychiatric side effects. Discuss these with your doctor if you have no thyroid cancer history.

Semaglutide (2.4 mg once-weekly) produces significant, sustained weight loss (10-15%) and improves cardiometabolic markers in non-diabetic individuals with obesity or overweight, primarily by mimicking GLP-1 to reduce appetite and energy intake.

If you have obesity or are overweight without diabetes, semaglutide (2.4 mg weekly) is a highly effective medical treatment that can help you lose 10-15% of your body weight and improve your metabolic health. It works by reducing your appetite. While it can cause temporary stomach issues like nausea, these often subside. It works best when combined with diet and exercise, but it is significantly more effective than lifestyle changes alone for substantial weight loss.

GLP-1 receptor agonists (semaglutide) and dual incretin agonists (tirzepatide) achieve 15-20% total body weight loss, rivaling the efficacy of bariatric surgery.

If you have obesity, these medications offer a powerful, non-surgical path to significant weight loss (15-20%). They require a weekly injection and likely lifelong use, but they can improve metabolic health and may be more accessible than surgery for some. Discuss with your doctor if you are a candidate.

GLP-1 receptor agonists (semaglutide and tirzepatide) produce significantly greater average weight loss (14.9% and 18.5%, respectively) than physicians estimate (9.22%), and are associated with high rates of gastrointestinal side effects (80-90%) that are significantly underestimated by prescribers.

If you are prescribing GLP-1 agonists, ensure you are counseling patients on the high likelihood of gastrointestinal side effects (up to 90%) and the significant magnitude of weight loss (15-18%). Underestimating these factors leads to poor adherence and unrealistic expectations.

Health Behavior Intervention (HBI) consisting of 13 dietician-led counseling sessions over 1 year is a cost-effective strategy for managing class III obesity compared to no treatment.

For individuals with class III obesity, engaging in 13 dietician-led counseling sessions over a year is a cost-effective way to manage weight and prevent complications, especially if surgery is not an option.